Brian Bahman Borg MD

Gastroenterology•New Orleans, LA

Hepatology & Liver Transplantation

Physician

Join to View Full Profile

131 S Robertson Street #8035 Suite 843New Orleans, LA 70112
Phone+1 504-512-0052
Fax+1 504-988-3048

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Gastroenterology, 2006 - 2009
Clinical Center at the National Institutes of HealthFellowship, Transplant Hepatology, 2003 - 2006
University of Maryland Capital Region HealthResidency, Internal Medicine, 2000 - 2003
Tehran University of Medical Sciences School of MedicineClass of 1992

Certifications & Licensure

CO State Medical License 2024 - 2027
LA State Medical License 2009 - 2026
MO State Medical License 2023 - 2026
MS State Medical License 2012 - 2025
KS State Medical License 2023 - 2024
MD State Medical License 2003 - 2018
American Board of Internal Medicine Gastroenterology

Clinical Trials

Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure Start of enrollment: 2013 Feb 01
Completed
Phase 3
Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Start of enrollment: 2014 Dec 26
Terminated
Phase 4
Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Start of enrollment: 2015 Jun 01
Completed
Phase 2
Study of Oral Treatments for Hepatitis C Start of enrollment: 2016 Jun 01
Completed
Phase 4
Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Oct 24
Terminated
Phase 2
Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) Start of enrollment: 2016 Nov 28
Completed
Phase 2
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124 Start of enrollment: 2016 Jul 31
Withdrawn
Early Phase 1
Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects Start of enrollment: 2017 Apr 20
Completed
Phase 3
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology Start of enrollment: 2017 Dec 08
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

18 citations
Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis.
Marlyn J Mayo, John M Vierling, Christopher L Bowlus, Cynthia Levy, Gideon M Hirschfield
Alimentary Pharmacology & Therapeutics. 2024-01-01
52 citations
Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Stephen A Harrison, Manal F Abdelmalek, Guy Neff, Nadege Gunn, Cynthia D Guy
The Lancet. Gastroenterology & Hepatology. 2022-07-01
50 citations
A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients with Nonalcoholic Steatohepatitis.
Mohammad S. Siddiqui, Michael O. Idowu, Deven Parmar, Brian B. Borg, Douglas Denham
Clinical Gastroenterology and Hepatology. 2021-12-01